Polynovo Limited (AU:PNV)
ASX:PNV
Want to see AU:PNV full AI Analyst Report?
PNV Stock Chart & Stats
AU$1.01
AU$0.01(0.49%)
At close: 4:00 PM EST
AU$1.01
AU$0.01(0.49%)
Day’s Range― - ―
52-Week RangeAU$0.87 - AU$1.72
Previous CloseN/A
Volume733.50K
Average Volume (3M)1.48M
Market Cap
AU$704.66M
Enterprise ValueAU$696.82M
Total Cash (Recent Filing)AU$29.26M
Total Debt (Recent Filing)AU$31.74M
Price to Earnings (P/E)70799.0
Beta1.79
Next Earnings
Aug 21, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding690,843,000
10 Day Avg. Volume1,478,953
30 Day Avg. Volume1,476,427
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)9.95
Price to Sales (P/S)6.51
P/FCF Ratio-76.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.74Price Target Upside72.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$150.68M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Improving ProfitabilityVery high gross margins (95.9%) alongside revenue growth and improved ROE signal durable product-level economics and pricing power. This margin profile supports reinvestment in clinical evidence, commercialization and scale without heavy gross-margin erosion as volumes expand.
U.S. Commercial Traction And Account ExpansionRapid account adds and double-digit U.S. sales growth indicate expanding penetration in hospital channels. A broadening installed base and >80 commercial reps create recurring, procedure-linked consumable demand and reduce unit adoption risk through deeper distributor and GPO coverage.
Regulatory And Clinical Progress (PMA, Evidence Base)A near‑term PMA pathway with BARDA partnership and a large peer‑reviewed evidence base meaningfully de‑riscos label expansion in a core indication. Planned RCTs and documented studies strengthen payor conversations and support sustainable, broader adoption across settings.
Bears Say
Weak Free Cash Flow ConversionSignificant negative FCF growth and low operating cashflow conversion limit self‑funding capacity for capex, trials and commercial rollouts. Until conversion improves, growth may require careful cash management or external funding, increasing execution risk during scale-up.
Outpatient Reimbursement UncertaintyOutpatient channel expansion hinges on CMS reimbursement clarity and likely RCT evidence. This creates structural timing and adoption risk: without coverage, commercially addressing the large outpatient market will be delayed or limited, constraining addressable market growth.
Lumpy Demand And Market VariabilityDependence on episodic, high‑variance procedures (burns) and tender delays in markets like India produce volatile volumes and uneven capacity utilization. This structural lumpy demand complicates forecasting, manufacturing cadence and the timing of revenue recognition as the business scales.
Polynovo News
PNV FAQ
What was Polynovo Limited’s price range in the past 12 months?
Polynovo Limited lowest share price was AU$0.86 and its highest was AU$1.72 in the past 12 months.
What is Polynovo Limited’s market cap?
Polynovo Limited’s market cap is AU$704.66M.
When is Polynovo Limited’s upcoming earnings report date?
Polynovo Limited’s upcoming earnings report date is Aug 21, 2026 which is in 118 days.
How were Polynovo Limited’s earnings last quarter?
Polynovo Limited released its earnings results on Feb 20, 2026. The company reported AU$0 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.006.
Is Polynovo Limited overvalued?
According to Wall Street analysts Polynovo Limited’s price is currently Undervalued.
Does Polynovo Limited pay dividends?
Polynovo Limited does not currently pay dividends.
What is Polynovo Limited’s EPS estimate?
Polynovo Limited’s EPS estimate is 0.01.
How many shares outstanding does Polynovo Limited have?
Polynovo Limited has 690,843,000 shares outstanding.
What happened to Polynovo Limited’s price movement after its last earnings report?
Polynovo Limited reported an EPS of AU$0 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -8.458%.
Which hedge fund is a major shareholder of Polynovo Limited?
Currently, no hedge funds are holding shares in AU:PNV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Polynovo Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$1.74 (72.28% Upside)
AU$1.74 (72.28% Upside)
Blogger Sentiment
Bullish
AU:PNV Sentiment 97%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $186.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.28%
12-Months-Change
Fundamentals
Return on Equity
11.87%
Trailing 12-Months
Asset Growth
17.90%
Trailing 12-Months
Company Description
Polynovo Limited
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
PNV Company Deck
PNV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and commercial picture: double‑digit revenue growth across major regions (group +26%, U.S. +25.3%, RoW +28.3%), rapid MTX adoption (~+193%), improved cash flow (+$9.0M) and a strong clinical evidence base (348 studies). Key strategic catalysts (PMA submission, SynPath outpatient pathway, expanded manufacturing capacity, recruitment of a Chief Scientific Officer) provide clear upside. Short‑term headwinds include a timing‑related manufacturing variance (~$3.6–3.7M) from planned slowdowns, an R&D lab fire asset write‑off (insured), FX translation losses, and reimbursement/regulatory uncertainty for outpatient CMS coverage which may require an RCT. Management frames several negatives as one‑offs or timing issues and expects margin and free cash flow improvement in H2. Overall, highlights materially outweigh the lowlights.View all AU:PNV earnings summariesPNV Stock 12 Month Forecast
Average Price Target
AU$1.74
▲(72.28% Upside)
Technical Analysis
Nova Eye Medical
―
Cochlear
―
Micro-X Ltd.
―
Aroa Biosurgery Ltd
―
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
―
Options Prices
Currently, No data available
---